DBV Technologies Stock: price and insider trades · France

DBV TECHNOLOGIES is a French biopharmaceutical company listed on Euronext Paris, focused on developing innovative treatments for food allergies and certain immunologic diseases. Founded in 2002 by pediatricians, the company was built around a clear scientific hypothesis: severe allergies may be treated more safely and effectively through epicutaneous immunotherapy. While its roots are in France, DBV Technologies has evolved into an international organization to support its clinical, regulatory and commercial programs, with a particularly important footprint in the United States, a key market for food-allergy therapies. The company now describes itself as a global clinical-stage biopharmaceutical group working to address conditions with significant unmet medical need.

DBV’s business is centered on its proprietary Viaskin® platform, a patch-based delivery system designed to administer tiny amounts of allergen through the skin in order to retrain the immune system. This approach, known as epicutaneous immunotherapy or EPIT, is the company’s main technological differentiator. Its flagship development program targets peanut allergy, with Viaskin® Peanut as the lead candidate and versions tailored to different pediatric age groups. Beyond peanut allergy, DBV also intends to explore broader applications for its technology in inflammatory and autoimmune diseases, which expands the long-term commercial opportunity beyond the food-allergy segment.